Introduction:Bilbert completed nearly 500 million yuan of strategic financing; Kekai Life Sciences won 350 million yuan of Pre-C round financing; Weilizhibo completed nearly 100 million US dollars of C-round financing
[Investment and Financing News October 8]Bilbert is a small tumor moleculeinnovateDrug developers are committed to the R&D of innovative drugs for cancer and other serious diseases, focusing on the R&D and industrialization of innovative class I new drugs for major diseases. They have the core technology of innovative drug design and R&D with independent intellectual property rights, and have the conditions from chemical synthesis to new drug discovery, from preclinical research to clinical development. Equity completed recentlyfinancingNearly 500 million yuan.
Kekai Life Sciences is a high-tech enterprise focusing on the research, development, production and sales of medical devices in the field of structural heart disease, developing system solutions for valve diseases in different populations, different needs and different scenarios. Recently, it was announced that it had received 350 million yuan of pre C financing.
Veritech is a clinical biopharmaceuticalcompany, founded by a senior antibody drug research and development team in the United States in Nanjing. It is committed to the research and development of new antibody drugs for cancer and other major diseases with independent intellectual property rights, focusing on the unmet medical needs, especially the problems and challenges faced by tumor immunotherapy. Nearly 1 completed recentlyYimeiRMB round C financing.
